

Bevacizumab GOG-0218

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Bevacizumab GOG-0218

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gynaecological Malignancies
Therapeutic Indication: Incompletely resected stage III and stage IV ovarian cancer
Experimental Arm: Bevacizumab + Carboplatin + paclitaxel
Control Arm: Paclitaxel and carboplatin (6 cycles)

